Skip to content
Orforglipron / Studies
Small molecule · 883 Da

Orforglipron studies and research data

PepBank has 56 orforglipron studies with results. 47 of them gave orforglipron, with 340 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 340 results and 150 papers. Newer studies from Europe PMC

Results in people
296
87% of 340 results
Results in animals
22
6% of 340 results
Results in lab cells
22
6% of 340 results
From computer models
0
0% of 340 results
The molecule

Orforglipron identity

Identifiers, parent molecule, targets and development stage, from curated data.

Orforglipron (LY3502970, OWL833) is a non-peptide small molecule, C48H48F2N10O5, about 883 Da, that binds and activates the human GLP-1 receptor. Chugai Pharmaceutical discovered it and Lilly licensed it in 2018 (Lilly release of 2026-09-30). The 2020 PNAS paper (PMID 33177239) describes it as a partial agonist biased toward G protein activation over beta-arrestin, with a cryo-EM structure (PDB 6XOX) that shows a binding pocket in the upper helical bundle of the receptor. The US label says it is not pharmacologically active in rats and mice and caused no rodent tumors. It is metabolised mainly by CYP3A4, reaches peak concentration 4 to 8 hours after a dose, and has an elimination half-life of about 29 to 49 hours; absolute bioavailability was 77 percent after a 0.8 mg dose (label sections 12.1 and 12.3). FDA approved the calcium salt as Foundayo tablets on 2026-04-01 under NDA 220934 (Type 1 new molecular entity), under the Commissioner's National Priority Voucher pilot, 50 days after filing (FDA bulletin of 2026-04-01). The US indication is, with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off in adults with obesity, or with overweight and at least one weight-related condition. The label dose is 0.8 mg once daily, stepped up after at least 30 days at each step through 2.5 mg and 5.5 mg to 9, 14.5 or 17.2 mg, with a maximum of 17.2 mg once daily, with or without food. The label has a boxed warning about thyroid C-cell tumors. The label says its trial data come from an investigational formulation and shows them as equivalent label dosages; published trials used capsule doses of 6, 12 and 36 mg (PMID 40960239). Lilly reported a US type 2 diabetes submission in the second quarter of 2026. As of 2026-10-13 no FDA decision on it was found, and the current US label lists weight management only. The UK MHRA authorised it on 2026-08-10 for weight management and for type 2 diabetes. The EMA lists an application for obesity and type 2 diabetes as under evaluation (data extracted 2026-10-05). The UAE Emirates Drug Establishment announced its approval on 2026-04-03 (press release carried by Zawya and TradeArabia), and the Saudi Food and Drug Authority approved the registration on 2026-08-02 (SFDA statement quoted by Khaleej Times). WADA does not name it on the 2026 or 2027 List. Before approval, research-chemical sellers sold products labelled orforglipron; Lilly said in October 2025 that no one could legally sell it for human use.

Kind
Small molecule
Formula
C48H48F2N10O5
Identifiers
ChEMBLCHEMBL4446782 (opens in a new tab)CHEMBL5314577 (opens in a new tab)PubChem CID137319706 (opens in a new tab)167713250 (opens in a new tab)UNII7ZW40D021M (opens in a new tab)VI5M9OZV2X (opens in a new tab)UV478AZB7Z (opens in a new tab)CAS2212020-52-32415797-61-2PDB6XOX (opens in a new tab)7E14 (opens in a new tab)KEGGD12536 (opens in a new tab)D12529 (opens in a new tab)IUPHAR12175 (opens in a new tab)
Development
Approved in the US (Foundayo, 2026)Eli Lilly and Company. Chugai Pharmaceutical (Japan) discovered the compound and Lilly licensed it in 2018.First approval: FDA, 2026-04-01 (Foundayo, weight management). Approved in the UK (weight management and type 2 diabetes, 2026-08-10), and by the regulators of the UAE (announced 2026-04-03) and Saudi Arabia (2026-08-02), as reported by regional news outlets. Under EMA evaluation for obesity and type 2 diabetes. Type 2 diabetes submitted to FDA in the second quarter of 2026 (no decision found). Lilly says it is also being studied for obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence (release of 2026-09-30). Pivotal US weight trials: Trial 1 (NCT05869903, 3,127 adults with obesity or overweight, no diabetes) and Trial 2 (NCT05872620, 1,613 adults with type 2 diabetes), both 72 weeks (label section 14). ACHIEVE-4 (NCT05803421, 2,749 adults with type 2 diabetes at higher cardiovascular risk) reported on 2026-09-30. ClinicalTrials.gov: 54 studies for 'orforglipron OR LY3502970 OR LY-3502970 OR OWL833' on 2026-10-13 (27 phase 3, 22 phase 1, 3 phase 2, 2 phase 4; 33 completed, 9 recruiting, 8 active not recruiting, 4 not yet recruiting; 50 led by Lilly). ChEMBL still shows max_phase 3.0 for the free base (CHEMBL4446782) and 1.0 for the calcium salt (CHEMBL5314577) on 2026-10-13, which does not match the 2026 approval. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
TargetActionEvidence
Glucagon-like peptide 1 receptorGLP1RP43220 (opens in a new tab)Agonistapproved-drug labelSource (opens in a new tab)

Structure

Structure from the identity record.

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 137319706(opens in a new tab)

C[C@H]1C[C@]1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)[C@H]5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7[C@@H]6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C
Results by area

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Trials and papers
Status and safety
Data

Compare